Chugai Pharmaceutical Co Ltd 2025 IR
The report highlights Chugai Pharmaceutical's record-high performance in fiscal year 2025, with revenue reaching 1,257.9 billion yen and operating profit growing for the ninth consecutive year to 623.2 billion yen. Key achievements include obtaining proof of concept for NXT007, successful Phase III trials and regulatory filings for orforglipron, and the acquisition of Renalys Pharma to secure rights for sparsentan. The company also launched its new job-based HR management system, formulated the Chugai AI Strategy, and established the Chugai Partnering US Office. On the environmental front, the company achieved its 2025 interim goals, reducing Scope 1 and 2 CO2 emissions by 55.8% compared to 2019.
Company: Chugai Pharmaceutical Co Ltd
Sector: Health Care
Country: Japan
Year: 2025
Type: IR
Pages: 44
Chugai Pharmaceutical Co Ltd
Annual Report
The report highlights Chugai Pharmaceutical's record-high performance in fiscal year 2025, with revenue reaching 1,257.9 billion yen and operating profit growing for the ninth consecutive year to 623.2 billion yen. Key achievements include obtaining proof of concept for NXT007, successful Phase III trials and regulatory filings for orforglipron, and the acquisition of Renalys Pharma to secure rights for sparsentan. The company also launched its new job-based HR management system, formulated the Chugai AI Strategy, and established the Chugai Partnering US Office. On the environmental front, the company achieved its 2025 interim goals, reducing Scope 1 and 2 CO2 emissions by 55.8% compared to 2019.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2025
Reporting Period
Jan 1, 2025 - Dec 31, 2025
Fiscal Year
2025
Type
Integrated Report
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
Materiality Assessment
ESG Data?Experimental — AI-extracted data, may contain inaccuracies
Water Consumption
Women in Management
Employees